Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers
Company Expects Global Registration Program to Begin for IDH2 inhibitor AG-221 in 2015 and IDH1 inhibitor AG-120 by early 2016
Agios Announces 2015 Upcoming Milestones for IDH Programs
"The durable responses observed for AG-221 with minimal toxicity being reported are impressive in this advanced disease setting," said Dr. Stein. "These findings build upon those presented throughout the year. In addition, they continue to provide evidence that AG-221 can inhibit the IDH2 mutant protein, stop production of the oncometabolite, 2-HG, and allow for cancer cells to become mature, functioning blood cells. This approach is different from traditional chemotherapy that attempts to non-selectively kill cancer cells. I believe AG-221's unique mechanism targeting a specific mutation is the way of the future and represents a highly specific oral therapy that may transform the treatment of a devastating group of blood cancers."
As of the data cut-off on
"We are making tremendous progress for patients with our AG-221 program, as the data from the Phase 1 study have consistently shown durable activity with a favorable safety profile in patients with several types of advanced hematologic malignancies, especially AML," said
About the Ongoing Phase 1 Trial for AG-221
The primary goals of the Phase 1 trial are to establish the safety profile, determine the maximum tolerated dose and assess the preliminary clinical activity of AG-221 as a single agent administered orally in 28-day cycles. The study is only enrolling patients who have an IDH2-mutant hematologic malignancy. Secondary objectives include characterization of the pharmacokinetics (PK) and pharmacodynamics (PD), including inhibition of 2-hydroxyglutarate (or 2HG). The trial uses an open-label, dose-escalating design. Data reported are from patients receiving AG-221 in 10 dose escalation cohorts administered from 60 mg to 300 mg total daily doses as of
A safety analysis was conducted for all 73 treated patients as of
October 1, 2014.
- The majority of adverse events reported by investigators were mild to moderate, with the most common being nausea, pyrexia, diarrhea and fatigue.
- The majority of serious adverse events (SAE) were disease related; SAE's possibly related to study drug were reported in 13 patients.
- 11 deaths were reported with nine unrelated to AG-221.
- Two deaths were reported as possibly related to study drug: one in a patient with sepsis and hypoxia and one with atrial flutter.
25 out of 45 efficacy evaluable patients achieved investigator accessed objective responses for an overall response rate of 56 percent as of the
- Of the 25 patients who achieved an objective response, there were six complete remissions, four complete remissions with incomplete platelet recovery (CRp), four marrow complete remissions (mCR), one complete remission with incomplete hematologic recovery (CRi) and 10 partial remissions (PR).
- Responses were durable, with duration on study drug as long as eight months and ongoing. An estimated 90 percent of responses are three months or longer, with four responders on AG-221 beyond six months of treatment.
- Ten patients with stable disease remain on AG-221, with several patients on study as long as six months and ongoing
- There have been no relapses in patients with a complete remission.
- Five patients were removed from the study per the protocol following decision to undergo a potentially curative bone marrow transplant.
- Treatment with AG-221 showed substantial reduction in the plasma levels of 2-HG to the level observed in healthy volunteers.
"Throughout 2014, we made significant progress across our company, in particular the achievement of proof-of-concept for two distinct IDH inhibitors, AG-221 and AG-120," said
Upcoming Milestones: Cancer Metabolism Program in Collaboration with
AG-221 (IDH2 mutant inhibitor): Multiple studies of AG-221 planned for 2015 support speed and breadth in development for patients with an IDH2 mutation
- Phase 1 expansion cohorts: In 2015, Agios expects to present data from the expansion cohorts in the ongoing Phase 1 study from 100 patients with IDH2-mutant hematologic malignancies, including AML.
- Global registration program: The company expects that a global registration program in hematologic malignances will start in 2015.
- Frontline therapy approach: In 2015, Agios plans to initiate combination trials in patients with AML to evaluate the potential of AG-221 as a first line therapy for patients with hematologic malignancies.
- Phase 1 solid tumor study: The company expects the Phase 1 trial in patients with advanced solid tumors whose cancers carry an IDH2 mutation to remain on track.
AG-120 (IDH1 mutant inhibitor): Multiple studies of AG-120 planned for 2015/2016 support speed and breadth in development for patients with an IDH1 mutation
- Phase 1 expansion cohorts: Agios plans to initiate expansion cohorts in hematologic malignancies as part of ongoing Phase 1 study in first half of 2015.
- Global registration program: The company plans to initiate a global registration program in hematologic malignances that harbor an IDH1 mutation by early 2016.
- Frontline therapy approach: Combination trials to evaluate potential frontline AML development are planned to begin in 2015.
- Phase 1 solid tumor study: The company remains on track to present the first data from the dose escalation portion of the Phase 1 advanced solid tumor trial at a medical conference in 2015.
Additional Presentation Highlighting Agios' IDH Programs
A poster presentation characterizing the PK/PD clinical data for AG-221 was also presented at the ASH meeting. The results showed that AG-221 has an excellent PK profile following oral dosing, with a high plasma exposure and long half-life, which supports once daily (QD) dosing. In addition, AG 221 suppressed the production of 2-HG to the normal range found in healthy volunteers. The PK (AG-221 exposure) and PD (the inhibition of 2-HG production) correlation supports the selection of 100 mg QD dosing of AG-221 in the ongoing Phase 1 expansion cohorts in hematologic malignancies.
Investor Event and Webcast
Agios will host a live event with webcast on
About Agios/Celgene Collaboration
AG-221 is a part of Agios' global strategic collaboration with
About IDH Mutations and Cancer
IDH1 and IDH2 are two metabolic enzymes that are mutated in a wide range of hematologic and solid tumor malignancies, including AML. Normally, IDH enzymes help to break down nutrients and generate energy for cells. When mutated, IDH increases production of an oncometabolite known as 2-hydroxyglutarate (2-HG) that alters the cells' genetic programming, and instead of maturing, the cells remain immature leukemic white blood cells, proliferate quickly and prevent mature infection-fighting white blood cells from developing. 2-HG has been found to be elevated in several tumor types. Agios believes that inhibition of the mutated IDH proteins may lead to clinical benefit for the subset of cancer patients whose tumors carry them. AG-221 was developed by Agios as a selective, potent inhibitor of the mutated IDH2 protein.
About Acute Myelogenous Leukemia (AML)
AML, a cancer of blood and bone marrow characterized by rapid disease progression, is the most common acute leukemia affecting adults. Undifferentiated blast cells proliferate in the bone marrow rather than mature into normal blood cells. AML incidence significantly increases with age, and according to the
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios' expectations and beliefs about: the potential of IDH1/2 mutations as therapeutic targets; the potential benefits of Agios' product candidates targeting IDH1 or 2 mutations, including AG-221 and AG-120; its plans and timelines for the research and clinical development and data presentations of AG-221 and AG-120; including the timing of a global registration program for each product candidate; and the benefit of its strategic plans and focus. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "potential," "could," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies: the content and timing of decisions made by the U.S.
CONTACT: Investor Contact:
Agios Pharmaceuticals, Inc. Lora Pikelora.firstname.lastname@example.org T: 617-649-8608 Media Contact: Dan Budwick, 973-271-6085 email@example.com